A phase II study of pembrolizumab plus chemotherapy with short-course radiotherapy as induction treatment for unresectable locally advanced esophageal squamous cell carcinoma: PALADIN trial.

Okemoto D, Kotani D, Nakamura M, Sato K, Kubo Y, Kadota T, Mishima S, Sakashita S, Hashimoto T, Bando H, Wakabayashi M, Rabinowitz M, Liu MC, Jurdi A, Yamaguchi T, Nishikawa H, Shitara K, Yano T, Kojima T, Fujita T

Open source

DOI: 10.1016/j.esmogo.2026.100342
Published: 2026 Jun
Container: ESMO gastrointestinal oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.esmogo.2026.100342,
  title = {A phase II study of pembrolizumab plus chemotherapy with short-course radiotherapy as induction treatment for unresectable locally advanced esophageal squamous cell carcinoma: PALADIN trial.},
  author = {Okemoto D and Kotani D and Nakamura M and Sato K and Kubo Y and Kadota T and Mishima S and Sakashita S and Hashimoto T and Bando H and Wakabayashi M and Rabinowitz M and Liu MC and Jurdi A and Yamaguchi T and Nishikawa H and Shitara K and Yano T and Kojima T and Fujita T},
  year = {2026},
  journal = {ESMO gastrointestinal oncology},
  doi = {10.1016/j.esmogo.2026.100342},
  url = {https://doi.org/10.1016/j.esmogo.2026.100342}
}

RIS

TY  - JOUR
TI  - A phase II study of pembrolizumab plus chemotherapy with short-course radiotherapy as induction treatment for unresectable locally advanced esophageal squamous cell carcinoma: PALADIN trial.
AU  - Okemoto D
AU  - Kotani D
AU  - Nakamura M
AU  - Sato K
AU  - Kubo Y
AU  - Kadota T
AU  - Mishima S
AU  - Sakashita S
AU  - Hashimoto T
AU  - Bando H
AU  - Wakabayashi M
AU  - Rabinowitz M
AU  - Liu MC
AU  - Jurdi A
AU  - Yamaguchi T
AU  - Nishikawa H
AU  - Shitara K
AU  - Yano T
AU  - Kojima T
AU  - Fujita T
PY  - 2026
JO  - ESMO gastrointestinal oncology
DO  - 10.1016/j.esmogo.2026.100342
UR  - https://doi.org/10.1016/j.esmogo.2026.100342
ER  -

APA

D, O., D, K., M, N., K, S., Y, K., T, K., S, M., S, S., T, H., H, B., M, W., M, R., MC, L., A, J., T, Y., H, N., K, S., T, Y., T, K., & T, F. (2026). A phase II study of pembrolizumab plus chemotherapy with short-course radiotherapy as induction treatment for unresectable locally advanced esophageal squamous cell carcinoma: PALADIN trial.. ESMO gastrointestinal oncology. https://doi.org/10.1016/j.esmogo.2026.100342

Source records

pubmed · retrieved 2026-09-26T22:09:37.861Z